109 related articles for article (PubMed ID: 27665742)
1. Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin, a novel drug for stimulation of appetite.
Zollers B; Huebner M; Armintrout G; Rausch-Derra LC; Rhodes L
J Vet Pharmacol Ther; 2017 Jun; 40(3):248-255. PubMed ID: 27665742
[TBL] [Abstract][Full Text] [Related]
2. A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite.
Zollers B; Wofford JA; Heinen E; Huebner M; Rhodes L
J Vet Intern Med; 2016 Nov; 30(6):1851-1857. PubMed ID: 27859746
[TBL] [Abstract][Full Text] [Related]
3. Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study.
Zollers B; Rhodes L; Heinen E
BMC Vet Res; 2017 Jan; 13(1):10. PubMed ID: 28056951
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the safety of daily administration of capromorelin in cats.
Wofford JA; Zollers B; Rhodes L; Bell M; Heinen E
J Vet Pharmacol Ther; 2018 Apr; 41(2):324-333. PubMed ID: 29057482
[TBL] [Abstract][Full Text] [Related]
5. Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult Beagle dogs.
Zollers B; Rhodes L; Smith RG
J Vet Pharmacol Ther; 2017 Apr; 40(2):140-147. PubMed ID: 27597271
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Effects of Capromorelin and Mirtazapine on Appetite in New Zealand White Rabbits (
Draper JM; Savson DJ; Lavin ES; Feldman ER; Singh B; Martin-Flores M; Daugherity EK
J Am Assoc Lab Anim Sci; 2022 Sep; 61(5):495-505. PubMed ID: 35981857
[TBL] [Abstract][Full Text] [Related]
7. Insights on discovery, efficacy, safety and clinical applications of ghrelin receptor agonist capromorelin in veterinary medicine.
Rathore M; Das N; Ghosh N; Guha R
Vet Res Commun; 2024 Feb; 48(1):1-10. PubMed ID: 37493940
[TBL] [Abstract][Full Text] [Related]
8. Capromorelin, a ghrelin receptor agonist, increases feed intake and body weight gain in broiler chickens (Gallus gallus domesticus).
Ceron-Romero N; Taofeek N; Thomas A; Vroonland E; Sanmartin K; Verghese M; Heinen E; Vizcarra JA
Poult Sci; 2021 Aug; 100(8):101204. PubMed ID: 34182219
[TBL] [Abstract][Full Text] [Related]
9. The effect of capromorelin on glycemic control in healthy dogs.
Pascutti KM; O'Kell AL; Hill RC; Castro RA; Salute ME; Gilor C
Domest Anim Endocrinol; 2022 Oct; 81():106732. PubMed ID: 35689953
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the Safety and Efficacy of Capromorelin in Rhesus Macaques (
Campellone GA; Easley KA; Jenkins JB; Jean SM
J Am Assoc Lab Anim Sci; 2024 Feb; ():. PubMed ID: 38423529
[TBL] [Abstract][Full Text] [Related]
11. Detection of capromorelin in urine following oral and dermal routes of administration.
Sobolevsky T; Walpurgis K; Goergens C; Fedoruk M; Lewis L; Ahrens B; Thevis M
Drug Test Anal; 2023; 15(11-12):1449-1453. PubMed ID: 37688359
[TBL] [Abstract][Full Text] [Related]
12. Effects of an oral growth hormone secretagogue in older adults.
White HK; Petrie CD; Landschulz W; MacLean D; Taylor A; Lyles K; Wei JY; Hoffman AR; Salvatori R; Ettinger MP; Morey MC; Blackman MR; Merriam GR;
J Clin Endocrinol Metab; 2009 Apr; 94(4):1198-206. PubMed ID: 19174493
[TBL] [Abstract][Full Text] [Related]
13. Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs.
Rhodes L; Zollers B; Wofford JA; Heinen E
Vet Med Sci; 2018 Feb; 4(1):3-16. PubMed ID: 29468076
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.
Garcia JM; Friend J; Allen S
Support Care Cancer; 2013 Jan; 21(1):129-37. PubMed ID: 22699302
[TBL] [Abstract][Full Text] [Related]
15. Discovery and biological characterization of capromorelin analogues with extended half-lives.
Carpino PA; Lefker BA; Toler SM; Pan LC; Hadcock JR; Murray MC; Cook ER; DiBrino JN; DeNinno SL; Chidsey-Frink KL; Hada WA; Inthavongsay J; Lewis SK; Mangano FM; Mullins MA; Nickerson DF; Ng O; Pirie CM; Ragan JA; Rose CR; Tess DA; Wright AS; Yu L; Zawistoski MP; Pettersen JC; DaSilva-Jardine PA; Wilson TC; Thompson DD
Bioorg Med Chem Lett; 2002 Nov; 12(22):3279-82. PubMed ID: 12392732
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the ghrelin agonist capromorelin in a single ascending dose Phase-I safety trial in spinal cord-injured and able-bodied volunteers.
Ellis AG; Zeglinski PT; Brown DJ; Frauman AG; Millard M; Furness JB
Spinal Cord; 2015 Feb; 53(2):103-8. PubMed ID: 25448190
[TBL] [Abstract][Full Text] [Related]
17. The effect of the ghrelin-receptor agonist capromorelin on glucose metabolism in healthy cats.
Pires J; Greathouse RL; Quach N; Huising MO; Crakes KR; Miller M; Gilor C
Domest Anim Endocrinol; 2021 Jan; 74():106484. PubMed ID: 32619812
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological and toxicological effects of chronic porcine growth hormone administration in dogs.
Prahalada S; Stabinski LG; Chen HY; Morrissey RE; De Burlet G; Holder D; Patrick DH; Peter CP; van Zwieten MJ
Toxicol Pathol; 1998; 26(2):185-200. PubMed ID: 9547855
[TBL] [Abstract][Full Text] [Related]
19. Studies of the toxicological potential of tripeptides (L-valyl-L-prolyl-L-proline and L-isoleucyl-L-prolyl-L-proline): IV. Assessment of the repeated-dose toxicological potential of synthesized L-valyl-L-prolyl-L-proline in male and female rats and dogs.
Nakamura Y; Bando I; Mennear JH; Bernard BK
Int J Toxicol; 2005; 24 Suppl 4():25-39. PubMed ID: 16419577
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.
Garcia JM; Polvino WJ
Growth Horm IGF Res; 2009 Jun; 19(3):267-73. PubMed ID: 19196529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
